Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has received the US Food and Drug Administration's nod to market a generic version of alprazolam, an anti-anxiety drug, in the US market. The company has received the USFDA's nod for marketing generic alprazolam tablets in four strengths, 0.25 mg, 0.55 mg, 1 mg and 2 mg, in the US market.

Generic alprazolam tablets are equivalent to Pfizer's patented Xanax tablets. Alprazolam has annual sales of USD 145 million in the United States. On Thursday, the company had received the US health regulator's nod for marketing a generic version of the Keppra injection, used for treating epilepsy, in the American market.